John B. Moriarty Sells 1,261 Shares of Alexion Pharmaceuticals, Inc. (ALXN) Stock

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) EVP John B. Moriarty sold 1,261 shares of the company’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $117.26, for a total transaction of $147,864.86. Following the sale, the executive vice president now owns 20,210 shares of the company’s stock, valued at $2,369,824.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Alexion Pharmaceuticals, Inc. (ALXN) traded up $2.24 during trading on Wednesday, hitting $117.15. 2,694,455 shares of the stock were exchanged, compared to its average volume of 1,820,000. The company has a current ratio of 2.96, a quick ratio of 2.51 and a debt-to-equity ratio of 0.35. The stock has a market capitalization of $26,170.00, a price-to-earnings ratio of 52.30, a P/E/G ratio of 0.94 and a beta of 1.16. Alexion Pharmaceuticals, Inc. has a one year low of $96.18 and a one year high of $149.34.

Institutional investors have recently bought and sold shares of the company. Valeo Financial Advisors LLC purchased a new stake in shares of Alexion Pharmaceuticals during the third quarter worth about $147,000. Dupont Capital Management Corp bought a new position in Alexion Pharmaceuticals in the third quarter worth about $156,000. BT Investment Management Ltd bought a new position in Alexion Pharmaceuticals in the third quarter worth about $165,000. Beacon Investment Advisory Services Inc. bought a new position in Alexion Pharmaceuticals in the third quarter worth about $201,000. Finally, Invictus RG bought a new position in Alexion Pharmaceuticals in the third quarter worth about $202,000. Institutional investors own 94.04% of the company’s stock.

ALXN has been the subject of several analyst reports. Zacks Investment Research upgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 price target for the company in a research report on Tuesday, October 31st. BidaskClub upgraded shares of Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, December 27th. Credit Suisse Group restated a “buy” rating and set a $166.00 price target on shares of Alexion Pharmaceuticals in a research report on Tuesday, December 12th. Stifel Nicolaus cut their price target on shares of Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating for the company in a research report on Tuesday, October 24th. Finally, UBS Group lowered shares of Alexion Pharmaceuticals from a “strong-buy” rating to an “outperform” rating in a research report on Thursday, January 4th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and twenty have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $153.10.

TRADEMARK VIOLATION WARNING: “John B. Moriarty Sells 1,261 Shares of Alexion Pharmaceuticals, Inc. (ALXN) Stock” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/07/john-b-moriarty-sells-1261-shares-of-alexion-pharmaceuticals-inc-alxn-stock.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Insider Buying and Selling by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply